/
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells ( Full Spectrum Profiling or FSP technology). Our goal is to become the premier cell analysis company through continued innov…
The business is unprofitable at the operating level (-20.04% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 0.5%, essentially flat. Margins also contracted 9.8pp. This is a business that needs a catalyst.
Free cash flow declined 140% versus the prior year, cash generation momentum has weakened. ROIC dropped from -3.99% to -8.33%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$204M
▲ +0.5% YoY
Net Income (TTM)
-$74M
▼ -1005.3% YoY
Op. Margin
-21.49%
▼ -9.8pp YoY
ROIC
-9.29%
▼ -4.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▼ -140.1% YoY
Op. Cash Flow (TTM)
-$7M
▼ -118.5% YoY
Net Debt
-$49M
Net Cash Position
Cash & Equiv.
$66M
5Y CAGR: +209.5%
Continue Research